Pediatric Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
New FDA committee will "provide advice and make recommendations to the commissioner...on matters relating to pediatric therapeutics, pediatric research and any other matter involving pediatrics for which the [FDA] has regulatory responsibility," the agency announces in a final rule slated for publication in the Aug. 2 Federal Register. The 12 voting members will bring experience in pediatric research, subspecialties, statistics and/or bioethics, including a patient organization rep and a "technically qualified member" with consumer interests. FDA also announces the creation of a pediatric ethics subcommittee and requests nominations in separate same-day notices. Formation of the panel is in accordance with the Pediatric Research & Equity Act (1"The Tan Sheet" Dec. 1, 2003, In Brief)...
You may also be interested in...
Pediatric Research Equity Act
S 650 "will provide FDA with additional authority to require pediatric studies of pharmaceutical products when such studies are needed to ensure the safe and effective use of the products in children," agency notes in Nov. 19 release. Bill was presented to President Bush Nov. 21. An amendment linking the expiration of the S 650 to the pediatric exclusivity incentive program remains in the bill (1"The Tan Sheet" Aug. 4, 2003, In Brief)...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.